type: misc

label: url

en: 癌患者における栄養素代謝の特徴

ja: 癌患者における栄養素代謝の特徴

en: 消化と吸収

ja: 消化と吸収


en: Nutritional therapy in Cancer treatment

ja: がん治療中の栄養管理 (特集 がん予防と食養生)

en: Clinical and Functional Nutriology

ja: 医と食


en: 高リン血症と低リン血症

ja: 高リン血症と低リン血症

en: 循環器医のための知っておくべき電解質異常

ja: 循環器医のための知っておくべき電解質異常


en: 栄養サポートチーム(NST)加算への対応

ja: 栄養サポートチーム(NST)加算への対応

en: The Journal of Metabolism and Clinical Nutrition

ja: 日本病態栄養学会誌


en: 肝硬変に対する栄養サポートのエビデンス

ja: 肝硬変に対する栄養サポートのエビデンス

en: 静脈経腸栄養

ja: 静脈経腸栄養


en: JIM, 疾患の結果として生じる栄養障害

ja: JIM, 疾患の結果として生じる栄養障害

en: JIM

ja: JIM


en: アルブミンは栄養評価の指標として適切か?

ja: アルブミンは栄養評価の指標として適切か?


en: 栄養評価における血清アルブミン値の考え方ー低栄養の指標としてのアルブミン?

ja: 栄養評価における血清アルブミン値の考え方ー低栄養の指標としてのアルブミン?

en: 臨床栄養

ja: 臨床栄養


en: 臨床スポーツ医学, 運動習慣形成と脳内神経伝達物質

ja: 臨床スポーツ医学, 運動習慣形成と脳内神経伝達物質

en: 臨床スポーツ医学

ja: 臨床スポーツ医学


en: 侵襲時の栄養評価法

ja: 侵襲時の栄養評価法

en: 機能性食品と薬理栄養

ja: 機能性食品と薬理栄養


en: Control of hypertension in metabolic syndrome

ja: メタボリック症候群における高血圧の管理

en: Metabolic syndrome includes abdominal obesity, hyperlipidemia, diabetes, and hypertension. All, but hypertension, are obviously related to metabolism. However, hypertension might result from, at least in part, abdominal obesity, because adipose tissue produces bioactive mediators (adipocytokines)which increase blood pressure. In treatment of hypertension, we should concern insulin resistance, which is a major risk factor of cardiovascular events. Angiotensin converting enzyme inhibitor is known to improve insulin resistance, but results of angiotensin receptor blocker in animal studies are controversial. In clinical trial, there are many established data that ARBs prevent new onset of diabetes mellitus, suggesting that this agent also has a beneficial effect on glucose metabolism. Short acting Ca-antagonists, such as nifedipine, decrease insulin sensitivity, but long-acting Ca-antagonists increase it. βblockers decrease insulin sensitivity but those with α-blocking action improve insulin resistance. Recent study, ARB is more potent to reduce cardiovascular risk in those with obesity than in those with normal body weight, suggesting some drugs are more effective in metabolic syndrome. Thus, when we chose antihypertensive drugs in treating patients with metabolic syndrome, we have to choose proper drugs in addition to modify life-style.

en: Shikoku Acta Medica

ja: 四国医学雑誌


en: The phytoestrogen ginsensoside Re activates potassium channels of vascular smooth muscle cells through PI3K/Akt and nitric oxide pathways

en: In vascular smooth muscle cells, large-conductance Ca(2+)-activated K(+) channels (K(Ca) channels) play a pivotal role in determining membrane potential, and thereby the vascular tone. Ginsenoside Re, a phytochemical from ginseng, is reported to activate this channel, but its precise mechanism is unsolved. Patch clamp studies showed that ginsenoside Re activates K(Ca) channels in the arterial smooth muscle cell line A10 in a dose-dependent manner. The channel-opening effect of ginsenoside Re was inhibited by 1 microM L-NIO, an inhibitor of eNOS, but not by 3 microM SMTC, an inhibitor of nNOS, indicating that ginsenoside Re activated K(Ca) channels through activation of eNOS. SH-6 (10 microM), an Akt inhibitor, and wortmannin, a PI3-kinase inhibitor, completely blocked activation of K(Ca) channels by ginsenoside Re, indicating that it activates eNOS via a c-Src/PI3-kinase/Akt-dependent mechanism. In addition, the ginsenoside Re-induced activation of eNOS and K(Ca) channel was blocked by 10 microM ICI 182, 780, an inhibitor of membrane estrogen receptor-alpha, suggesting that eNOS activation occurs via a non-genomic pathway of this receptor. In conclusion, ginsenoside Re releases NO via a membrane sex steroid receptors, resulting in K(Ca) channel activation in vascular smooth muscle cells, promoting vasodilation and preventing severe arterial contraction.

en: The Journal of Medical Investigation : JMI


en: 筋肉をつけるための栄養学

ja: 筋肉をつけるための栄養学

en: The Journal of Therapy

ja: 治療


en: 肝疾患の病変と栄養管理-解決すべき問題点 「肝硬変への分割食と就寝前軽食-その効果と課題」

en: 日本病態栄養学会誌


en: 心疾患診断ツールとしての心磁図

ja: 心疾患診断ツールとしての心磁図

en: The Journal of Japan Biomagnetism and Bioelectromagnetics Society

ja: 日本生体磁気学会誌


en: 心磁図の臨床応用‐徳島大学における研究‐

ja: 心磁図の臨床応用‐徳島大学における研究‐

en: マグネティックス研究会

ja: マグネティックス研究会


en: 冠動脈平滑筋細胞Kチャンネルに対するCalcitonin Gene-related Peptide (CGRP)の作用

en: Ther Res

ja: Ther Res


en: 血管平滑筋のカリウムチャンネルと収縮

ja: 血管平滑筋のカリウムチャンネルと収縮

en: BIO Clinica

ja: BIO Clinica


en: プロテインカイネースAおよびCの血管平滑筋単一K電流に対する作用

ja: プロテインカイネースAおよびCの血管平滑筋単一K電流に対する作用


en: 心磁界計測による不整脈発生源の推定

ja: 心磁界計測による不整脈発生源の推定

en: Medicina Philosophica

ja: 病態生理


en: A Patient with sustained ventricular tachycardia:identification of a responder to aminodarone using signal-averaged electrocardiogram

en: A 75-year-old man suffered sustained ventricular tachycardia with syncopal attack. Ventricular tachycardias appeared repeatedly, and an electrical defibrillator was used after an anti-arrhythmic drug, such as lidocaine or mexiletine, proved ineffective. The tachycardias had multiple origins, and the signal-averaged electrocardiogram (SAECG) showed ventricular late potential before the administration of amiodarone. After administration, the filtered QRS and duration of the late potential increased, but the recurrence of tachycardias was suppressed. The reason for this is thought to be that amiodarone blocked the sodium channel and delayed conduction, consequently blocking reentry, because amiodaron has antiarrhymic properties with a prolongation of refractoriness and minimal effect on conduction velocity in ventricular myocardium, and inhibits sympathetic activity, and blocks L-type calcium channel besides the depression of the fast sodium channel. In this case, SAECG predicted to some degree whether or not this patient's ventricular tachycardia would respond to amiodarone.

ja: The Journal of Medical Investigation : JMI

misc_type: others


en: THPによる健康増進の効果と生活習慣病の予防に関する調査研究報告書

ja: THPによる健康増進の効果と生活習慣病の予防に関する調査研究報告書

en: 調査研究報告書

ja: 調査研究報告書